Literature DB >> 8675091

Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass.

D S Bansi1, K A Fleming, R W Chapman.   

Abstract

Antineutrophil cytoplasmic antibodies (ANCA) have been reported in up to 87% of patients with primary sclerosing cholangitis with or without ulcerative colitis (PSC +/- UC) and in 68% of those with UC only. Compared with other liver and diarrhoeal diseases, ANCA have high specificity for PSC (+/- UC) and UC only. This study aimed to determine the prevalence and significance of ANCA in these two diseases and whether the ANCA titre or IgG subclass, or both, could distinguish between PSC + UC and UC only. Subjects included 63 patients with PSC, 85 with UC, 17 with coeliac disease, and 10 with dermatitis herpeteformis and 36 normal subjects. ANCA was detected using the immunoalkaline phosphatase method. The IgG subclass of ANCA was determined in 27 PSC + UC and 30 UC only patients using a panel of mouse monoclonal antibodies specific for the IgG subclasses. At a serum dilution of 1:5, ANCA had a diagnostic sensitivity of 65% for all PSC and 45% for UC only. For PSC + UC the sensitivity was 70% at 1:5 (p = 0.004 v UC only). At 1:50, the sensitivity values were 54% and 25% respectively for PSC + UC and UC only (p = 0.0006). In PSC, ANCA positivity was significantly associated with extensive involvement of the biliary tree but not with other clinical parameters. In UC only, the median disease duration was significantly greater in ANCA positive patients. The PSC + UC ANCA showed increased IgG3 compared with UC only ANCA (p < 0.05), together with increased IgG2 and IgG4 (p = NS). ANCA is a diagnostic marker in PSC and UC. While the higher titres and different IgG subclass distribution of ANCA in PSC + UC patients compared with those with UC only may reflect differences in underlying immune regulation, determination of the ANCA titre and IgG subclass is unlikely to have a role in distinguishing between PSC + UC and UC only ANCA. Future identification of the antigen(s) for ANCA should allow the development of a more sensitive and specific test for the diagnosis of these two conditions and also determine if ANCA is associated with UC or PSC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8675091      PMCID: PMC1383067          DOI: 10.1136/gut.38.3.384

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  21 in total

1.  beta-Glucuronidase antibodies in ulcerative colitis.

Authors:  L Nässberger; A Ljungh; G Schumacher; B Kollberg
Journal:  Lancet       Date:  1992-09-19       Impact factor: 79.321

2.  Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1955-10-29

3.  Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis.

Authors:  R H Duerr; S R Targan; C J Landers; N F LaRusso; K L Lindsay; R H Wiesner; F Shanahan
Journal:  Gastroenterology       Date:  1991-05       Impact factor: 22.682

4.  Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis.

Authors:  F Seibold; P Weber; R Klein; P A Berg; K H Wiedmann
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

5.  Significance and specificity of antibodies to neutrophils detected by western blotting for the serological diagnosis of primary sclerosing cholangitis.

Authors:  R Klein; J Eisenburg; P Weber; F Seibold; P A Berg
Journal:  Hepatology       Date:  1991-12       Impact factor: 17.425

6.  Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease.

Authors:  E Peen; S Almer; G Bodemar; B O Rydén; C Sjölin; K Tejle; T Skogh
Journal:  Gut       Date:  1993-01       Impact factor: 23.059

7.  Is p-ANCA in ulcerative colitis directed against beta-glucuronidase?

Authors:  K Kaneko; Y Suzuki; Y Yamashiro; K Yabuta
Journal:  Lancet       Date:  1993-01-30       Impact factor: 79.321

8.  IgG subclass distribution of autoantibodies to neutrophil cytoplasmic antigens in systemic vasculitis.

Authors:  D R Jayne; A P Weetman; C M Lockwood
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

9.  Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis.

Authors:  L Halbwachs-Mecarelli; P Nusbaum; L H Noël; D Reumaux; S Erlinger; J P Grünfeld; P Lesavre
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

10.  Prevalence of anti-neutrophil antibody in primary sclerosing cholangitis and ulcerative colitis using an alkaline phosphatase technique.

Authors:  S K Lo; K A Fleming; R W Chapman
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

View more
  21 in total

1.  Autoantibodies to molecular targets in neutrophils in patients with ulcerative colitis.

Authors:  J Brimnes; O H Nielsen; A Wiik; N H Heegaard
Journal:  Dig Dis Sci       Date:  1999-02       Impact factor: 3.199

Review 2.  Primary sclerosing cholangitis.

Authors:  S A Mitchell; R W Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

3.  Diagnostic approach to patients with cholestatic jaundice.

Authors:  N Assy; G Jacob; G Spira; Y Edoute
Journal:  World J Gastroenterol       Date:  1999-06       Impact factor: 5.742

4.  Primary sclerosing cholangitis in association with multiple myeloma.

Authors:  Nasrollah Ahmadpour; Matthew Downey; Elizabeth Frauenhoffer; Thomas Riley; Ian R Schreibman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-08

Review 5.  Autoantibodies in primary sclerosing cholangitis.

Authors:  Johannes-Roksund Hov; Kirsten-Muri Boberg; Tom-H Karlsen
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

6.  Antineutrophil cytoplasmic antibodies in Bulgarian patients with rheumatoid arthritis: characterization and clinical associations.

Authors:  Irena Manolova; Maria Dantcheva
Journal:  Rheumatol Int       Date:  2004-11-11       Impact factor: 2.631

7.  pANCA antibodies in patients with anterior uveitis: identification of a marker antibody usually associated with ulcerative colitis.

Authors:  L K Gordon; M Eggena; G N Holland; J M Weisz; J Braun
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

Review 8.  Characterization of animal models for primary sclerosing cholangitis (PSC).

Authors:  Peter Fickert; Marion J Pollheimer; Ulrich Beuers; Carolin Lackner; Gideon Hirschfield; Chantal Housset; Verena Keitel; Christoph Schramm; Hanns-Ulrich Marschall; Tom H Karlsen; Espen Melum; Arthur Kaser; Bertus Eksteen; Mario Strazzabosco; Michael Manns; Michael Trauner
Journal:  J Hepatol       Date:  2014-02-19       Impact factor: 25.083

Review 9.  Primary sclerosing cholangitis: diagnosis, prognosis, and management.

Authors:  Siddharth Singh; Jayant A Talwalkar
Journal:  Clin Gastroenterol Hepatol       Date:  2013-02-27       Impact factor: 11.382

10.  Antibodies against hepatoma-derived growth factor and mucosal repair in ulcerative colitis.

Authors:  Hideji Nakamura; Kenya Yoshida; Kazuhiro Ikegame; Yoshihiko Kishima; Hirokazu Uyama; Hirayuki Enomoto
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.